Imagenetix Announced the Publication of Its Clinical Study in The Journal of Rheumatology SAN DIEGO, April 1 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News) —
For the 70 million people who suffer from arthritis and many millions more who suffer from chronic pain, there is now a safe and effective way to experience fast relief. A new study conducted by the University of Connecticut found Imagenetix's arthritis topical cream, Celadrin®, may significantly benefit those suffering from arthritis. The results of this clinical study were published today in The Journal of Rheumatology, a publication that provides an international forum for rheumatological topics in published format.
In the study, all of the patients who applied Celadrin® (a complex of cetylated fatty acids) as opposed to the placebo cream, demonstrated significant improvement in all five physical function measurements. Patients were assessed for physical function, pain levels, range of motion, postural sway, timed up and go from a chair, timed stair climbing and medial step-down. For every measure, the difference between the Celadrin® cream group and placebo cream group was significant, including reduction in pain and stiffness, improvement in supine range of motion of the osteoarthritic knee, less postural sway and reductions in time in both the up and go and the stair climbing tests.
Subscribe to the World's Most Popular Newsletter (it's free!)
According to William Kraemer, Ph.D., from the University of Connecticut, "The scientific findings were quite impressive and are very encouraging. Osteoarthritis is a complex condition which is typically treated using nonsteroidal, anti-inflammatory drugs. These findings show that a topical cream can be a very effective and viable alternative. It is exceptionally impressive that 100% of the patients using Celadrin® topical cream reported significant benefit when compared to the placebo group, with no reported side effects." "The benefits shown in this unique and landmark research continue to scientifically validate the strong efficacy profile of Celadrin® topical cream," said Robert Hesslink, Jr., Sc.D., Imagenetix Director of Research and co-author of the study. "The findings demonstrate that persons who suffer with arthritis, and who live with tremendous mobility restrictions and pain can benefit from Celadrin® topical cream."
Celadrin® is a novel compound developed through a proprietary process. Celadrin® is an all-natural ingredient which has been clinically shown to provide joint health, flexibility and improved quality of life on a cumulative basis with no reported side effects.
About Imagenetix, Inc. San Diego based Imagenetix, Inc., (OTC Bulletin Board: IAGX – News) www.Imagenetix.net , is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human and animal health on a global basis. The company develops, formulates, and private-labels proprietary and leading health products to be marketed globally through multiple channels of distribution. For patented products, Imagenetix explores licensing arrangements with appropriate pharmaceutical partners. Safe Harbor Statement
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission. Source: Imagenetix, Inc.